-- 据周三提交给香港交易所的文件显示,制药公司SSY集团(HKG:2005)宣布,其三款产品已获得中国国家药品监督管理局的批准,可在中国大陆进行生产和注册。 此次获得批准的产品包括:脂溶性维生素注射剂、用于治疗2型糖尿病的盐酸二甲双胍片,以及用于治疗良性前列腺增生和高血压的甲磺酸多沙唑嗪缓释片。
Related Articles
Aurizon Holdings Welcomes Australia's AU$1.75 Billion Investment to Improve Freight Rail Network
Aurizon Holdings (ASX:AZJ) welcomed the AU$1.75 billion investment announced by the Australian government overnight to improve Australia's freight rail network, according to a Wednesday Australian bourse filing.The firm's Chief Executive, Andrew Harding, noted that increased extreme weather events, as well as the long-term deterioration of track infrastructure, led to an adverse impact on the rail industry in recent years.The government indicated the funds will be used for initiatives such as resilience upgrades in high-risk flood-prone areas of the network, as well as on track renewal works, passing loop extensions, and improved signalling.Harding added that the government's decision to pause work on the Inland Rail was prudent and fiscally responsible.
Dana Gas Partners With UK's Levidian for Graphene Production in UAE
Dana Gas (ADX:DANA) is collaborating with UK-based advanced materials company Levidian to produce graphene in Sharjah, United Arab Emirates.The partners plan to develop the Sharjah Graphene Park in phases, initially deploying Levidian's LOOP technology, which converts methane into graphene and hydrogen, to establish local production capability, the natural gas company said Wednesday. The project is expected to scale into a multi-unit production cluster following the initial phase.The first phase is estimated to cost between $2 million and $5 million, while early expansion could require $5 million to $50 million, with the potential to exceed $50 million as the project develops in line with market demand.
Ora Banda Mining's Execution of Exploration Program Creates Strong Foundation for Self‐Funded Growth, Euroz Hartleys Says
Ora Banda Mining's (ASX:OBM) execution of its ambitious fiscal year 2026 exploration program established a solid foundation for self‐funded growth, Euroz Hartleys said in a May 5 note.The exploration program was underpinned by a budget of AU$73 million and roughly 330 kilometers of drilling, an investment that has already yielded a 57% boost in group resources to 3.3 million ounces with more near-term growth on the horizon, the equity research firm said.The company's Waihi gold prospect in Western Australia "is advancing rapidly from a small open pit to portal position for the next underground mine," Euroz Hartleys said.It added that the Riverina and Sand King underground mines are running at steady‐state and appear to be supporting long mine lives, with Sand King continuing to benefit from dual declines and a recent 25% uplift in mined ounces.Euroz Hartleys maintained a buy rating on Ora Banda and raised its price target to AU$1.92 per share from AU$1.88, saying the company "remains a compelling growth story leveraged to exploration success."